logo
Share SHARE
FONT-SIZE Plus   Neg

New Data On Novartis' Lucentis Confirms Benefits Of Individualized Treatment

Novartis AG (NVS) said new data for Lucentis (ranibizumab), the only anti-VEGF therapy licensed across three ocular indications, show that individualized treatment with Lucentis provides sustained improvement in vision with a low number of injections.

In addition, Lucentis exhibited benefits in visual acuity outcomes in patients with visual impairment due to choroidal neovascularization secondary to pathological myopia. At present, Lucentis is not approved to treat this condition. Novartis noted that it will submit for regulatory approval in this indication in the European Union in the third quarter of this year and in Japan by late 2012.

Tim Wright, Global Head of Development, Novartis Pharma, commented, "Lucentis has become the standard of care in wet AMD and has helped to significantly improve vision in a majority of patients with this disease. These new data confirm that an individualized treatment approach can lead to optimal improvements in vision with a low average number of treatments, thus ensuring that patients with retinal diseases are not over- or under-treated. In addition, these data add to the well-characterized safety profile of Lucentis."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The biotech space is not for the faint hearted, given the ebbs and flows in terms of the returns from investing in it. However, for one who perseveres and astutely devises strategies with full cognizance of key regulatory events coming up, the probability of drug candidates getting FDA's blessings and sympathy plays in the space, it provide a sea of opportunity and huge upside prospects. Alcobra Ltd.'s Investigational New Drug Applications for drug candidate MDX in Attention Deficit Hyperactivity Disorder and Fragile X Syndrome have been put on full clinical hold, following adverse neurological findings in a pre-clinical study. Chinese conglomerate Dalian Wanda is in talks to buy Dick Clark Productions, as the company aims to expand in to the US entertainment industry. According to reports, Dalian Wanda Group has started preliminary talks to buy Dick Clark Productions for a price of about $1 billion. Dick Clark Productions...
comments powered by Disqus
Follow RTT